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Background: Reproducibility and hemodynamic efﬁcacy of optimization of AV delay (AVD) of cardiac resynchro-
nization therapy (CRT) using invasive LV dp/dtmax are unknown.
Method and results: 25 patients underwent AV delay (AVD) optimisation twice, using continuous left ventricular
(LV) dp/dtmax, systolic blood pressure (SBP) and pulse pressure (PP). We compared 4 protocols for comparing
dp/dtmax between AV delays:
Immediate absolute: mean of 10 s recording of dp/dtmax acquired immediately after programming the tested AVD,
Delayed absolute: mean of 10 s recording acquired 30 s after programming AVD,
Single relative: relative difference between reference AVD and the tested AVD,
Multiple relative: averaged difference, from multiple alternations between reference and tested AVD.Weassessed for dp/dtmax, LVSBP and LVPP, test–retest reproducibility of the optimum.Optimization using immediate
absolute dp/dtmax had poor reproducibility (SDD of replicate optima=41 ms; R2=0.45) as did delayed absolute
(SDD 39 ms; R2=0.50). Multiple relative had better reproducibility: SDD 23 ms, R2=0.76, and (pb0.01
by F test).Compared with AAI pacing, the hemodynamic increment from CRT, with the nominal AV delay was
LVSBP 2% and LVdp/dtmax 5%, while CRT with pre-determined optimal AVD gave 6% and 9% respectively.
Conclusions: Because of inevitable background ﬂuctuations, optimization by absolute dp/dtmax has poor same-day
reproducibility, unsuitable for clinical or research purposes. Reproducibility is improved by comparing to a reference
AVD and making multiple consecutive measurements. More than 6 measurements would be required for even
moreprecise optimization— andmight be advisable for future study designs.With optimal AVD, instead of nominal,
the hemodynamic increment of CRT is approximately doubled.© 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Test–retest reproducibility of the identiﬁed optimum is a sine qua non
of any process of optimization of AV delay for cardiac resynchronization
therapy (CRT) [1]. If immediately-successive attempts at optimizationupport from the British Heart
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er CC BY-NC-ND license.yield very different results, then either the optimum is really changing
dramatically (in which case there is no point in trying to optimize) or
the optimization process is not reliably identifying the optimum, because
the protocol has not done enough to counteract the intrinsic baseline
variability of the measured variable. An unreliable optimization process
may cause physiological harm if it causes AV delay to be programmed
to a worse value than nominal.
Invasive left ventricular (LV) dp/dtmax measurements are used to
guide optimization of cardiac resynchronization therapy devices [2,3],
because they directly assay the effects of AV delay on cardiac contrac-
tion. On the strength of their directness, they are often used as a gold
standard against which other candidate variables for optimization can
be compared [4,5], as well as a tool for assessing the impact of LV pacing
site during CRT [6].
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not re-analysis of identical datasets) is a useful prelude to instituting a
method into clinical practice or embarking on a clinical outcome trial.
Without this, if an outcome trial does not show beneﬁts from optimiza-
tion, it is not possible to distinguish between AV delay being unimportant
versus the tested method being unreproducible [7], even if the trial is
meticulously conducted and large-scale.
A reliable method for assessing the impact of adjusting the settings
of resynchronization devices is a pre-requisite for studies investigating
the mechanism through which they deliver their beneﬁcial effect.
1.1. Processing of LV dp/dtmax
Measurements of LV dp/dtmax at each AV delay setting may be
expressed absolutely (immediately after changing the AV delay, or after
a delay for stabilisation); or by comparison to the measurement of a ref-
erence delay (recorded immediately prior to changing to the tested AV
delay, or after a delay for stabilisation). A wide variety of protocols have
been described in the literature for acquiring LV dp/dtmax including the
following:
• measuring absolute dp/dtmax after a 30 second stabilisation period
for a duration of 30 s [8].
• waiting 20 s and then recording dp/dtmax for ≥1 respiratory cycle,
and calculating the average dp/dtmax over that time period [3].
• the relative value of dp/dtmax recorded after a 2 minute stabilisation
period following the transition to the tested AV delay [9].
• the average dp/dtmax derived from 10 consecutive paced beats,
starting from the third beat after the new pacing mode was applied,
compared to a baseline measurement taken at the end of the optimi-
zation sequence [10].
• comparing each tested AV delay to a reference state recorded immedi-
ately prior to the transition to the tested AV delay and performing re-
peated measurements between the tested AV delay and the reference
state [2,11].
1.2. Choice of invasive variable
Even though LV dp/dtmax is widely accepted as the gold standard,
others have also been used, including aortic pulse pressure and LV sys-
tolic pressure [2]. It is unclear whether they are acceptable, as to our
knowledge no studies have assessed the test–retest reproducibility of
AV delay optimization performed using these measures.
Several questions about dp/dtmax optimization remain unknown:
1. What is the test–retest reproducibility of optimization by dp/dtmax
using the current most widely-used processing method of delayed
absolute?
2. Do alternative methods of processing dp/dtmax, such as subtraction
from reference measurements, provide any advantage?
3. Does the process of peak slope calculation (dp/dtmax) give worth-
while improvement in precision of identiﬁcation of the optimum,
versus LV systolic pressure or LV pulse pressure?
In this study we address these questions by determining test–
retest reproducibility of optimization in patients undergoing invasive
optimization.
1.3. The biological determinants of reproducibility
Optimization relies on detection of potentially small hemody-
namic differences between AV delay settings, in an environment of
ever-present biological variability. If the genuine hemodynamic dif-
ferences between AV delays (the “signal”) are large, optimization is
easy; if they are small, optimization is difﬁcult. Meanwhile, if biolog-
ical variability (the “noise”) between one measurement and a repeat
measurement shortly afterwards, is large, optimization is difﬁcult; ifit is small, optimization is easy. When embarking on optimization, it
is therefore preferable to use an approach with high signal-to-noise
ratio. In this study we assess head-to-head signal-to-noise ratios
for three hemodynamic variables.
2. Methods
2.1. Subjects
25 patients who had cardiac resynchronization pacemakers (CRT-P) or cardiac
resynchronization therapy deﬁbrillators (CRT-D) implanted for clinical indications
(NYHA II–IV heart failure, QRS>120 ms or echocardiographic evidence of mechanical
dyssynchrony, maximalmedical therapy) were enrolled into this study. AV delay optimiza-
tionwas performedusing invasive hemodynamicmeasurements. Thiswas carried out up to
3 days post-implantation. 21 were male, 4 were female, mean age 64 years (min 34, max
78). Cause of heart failure was ischemic in 14, idiopathic dilated in 10, and chemotherapy
in 1. The ejection fraction of the patients at the time of the study was 27±5%. 11 patients
were in NYHA class II, 13 were in NYHA III, and 1 was in NYHA IV. 19 patients were taking
beta-blockers, 21 ACE inhibitors or AII antagonists, 10 spironolactone and 17 were taking
other diuretics. An informed consentwas obtained fromeachpatient and the studyprotocol
conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reﬂected in a priori
approval by the institution's human research committee.
2.2. Measurements
2.2.1. Data acquisition
While changing the AV delay of a patients' cardiac resynchronization therapy
(CRT) device, we recorded beat-by-beat left ventricular (LV) systolic blood pressure,
left ventricular pulse pressure (deﬁned as peak minus trough during the cardiac
cycle) and left ventricular dp/dtmax, all of which were measured invasively from
within the left ventricle using a 0.014-inch-diameter high ﬁdelity pressure wire
(Radi wire St. Jude Medical, Inc., St. Paul, MN, USA). The pressure wire was introduced
via the radial approach in 23 patients and via the femoral approach in the remaining 2
patients.
A continuous ECG signal was recorded using a Dynascope DS-7100 (Fukuda Denshi
USA) monitor. Analog output signals were taken via National instruments DAQ-Card
AI-16E-4 (National Instruments, Austin, TX) and acquired in digital form using Labview
(National Instruments, Austin, TX). They were analysed off line with custom software
based on the Matlab platform (MathWorks, Natick, MA) [12].
2.2.2. AV delay optimization
We tested a range of AV delays; potentially these were 40, 80, 120, 160, 200, 240,
280, 320 and 350 ms. In practice, for each subject we did not study AV delays beyond
the point at which conduction became purely intrinsic. Intrinsic rhythm was identi-
ﬁed using a 3 lead ECG recording and by comparing morphology with that occurring
during AAI pacing. The heart rate was kept constant throughout the study with atrial
pacing at a rate of 90 bpm. The interventricular delay was left at 0 ms or as close to
this as the device allowed. We tested each range of AV delays twice so that it was
possible to determine the test–retest reproducibility for each of the tested
parameters.
In order to identify the ‘optimal’ AV delay for each tested sequence of AV delays we
applied a quadratic equation to identify the peak of the parabola and therefore the AV
delay associated with the highest value of the measured hemodynamic parameter [13].
However, if the longest tested AV delay resulted in the highest hemodynamic value,
then this was taken as the ‘optimal’ AV delay since in this situation the quadratic equation
cannot be applied as it requires data points on either side of the peak in order to be
reliable.
2.2.3. Tested protocols for using LV dp/dtmax for optimization
We recorded beat-by-beat invasive dp/dtmax from the left ventricle while
adjusting the AV delay of the CRT device. We tested four different protocols for pro-
cessing the dp/dtmax signal. For each tested protocol we determined the test–retest
reproducibility with regard to the AV delay determined as optimal. We tested the fol-
lowing four protocols (Fig. 1):
(1) Immediate absolute LV dp/dtmax: the mean LV dp/dtmax recorded during a
window of 10 s commenced immediately after the transition to the tested
AV delay.
(2) Delayed absolute LV dp/dtmax: themean LV dp/dtmax recorded during awindowof
10 s commenced30 s after the transition to the testedAVdelay, i.e. permitting some
time for stabilisation before recording.
(3) Single relative LV dp/dtmax: the relative change in LV dp/dtmax measured with a
single transition between a reference AV delay (120 ms) and the tested AV
delay. This was calculated as the difference of the mean of the 10 beats im-
mediately before a transition and the mean of the 10 beats immediately
after.
(4) Multiple relative LV dp/dtmax: the mean relative change in LV dp/dtmax cal-
culated from a total of six transitions. For example, when testing 160 ms,
the AV delay was changed from 120 to 160 to 120 to 160 to 120 to 160
to 120 ms, allowing at least 20 beats in each state. This provided 6
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Fig. 1. Description of the four tested protocols for processing the dp/dtmax signal for AV delay optimization. (a) Immediate absolute LV dp/dtmax protocol: mean of a 10 second recording com-
menced immediately after a transition to the testedAVdelay (not compared to a reference setting). (b)Delayed absolute LVdp/dtmax protocol:meanof a 10 second recording commenced after
a 30 second stabilisation period following the transition to the tested AV delay. (c) Single relative LV dp/dtmax protocol: the relative change in LV dp/dtmax measured with a single transition
between a reference AV delay (120 ms) and the tested AV delay. (4) Multiple relative LV dp/dtmax: the mean relative change in LV dp/dtmax calculated from a total of six transitions to and
from the tested AV delay (three forward transitions to the tested AV delay and three back transitions to the reference AV delay, reversing the sign for the back transitions).
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160 ms and three “reverse” transitions from 160 to 120 ms whose blood
pressure effect we reversed in sign [11,13].
2.2.4. Comparison of different invasive hemodynamic parameters
We compared three different invasive hemodynamic variables that might be
used to guide AV delay optimization: left ventricular systolic blood pressure (SBP),
pulse pressure (PP), and left ventricular dp/dtmax. For this part of the study we
used themultiple relative protocol (mean of 3 forward and 3 back transitions between
tested and reference AV delay).
We compared these different hemodynamic parameters with respect to reproducibility
and precision.
2.3. Deﬁnition of reproducibility
In this paper, reproducibility of the AV delay optimum refers to whether the op-
timization process carried out with separate datasets identiﬁes a similar AV delay as
optimal. For each patient, one optimum (AVopt1) was calculated from one dataset,
and a second optimum (AVopt2) from a second dataset. The difference from the ﬁrst
to the second (AVopt1–AVopt2) was calculated for each patient. The mean value of
this difference is not of interest as there is no reason for the second optimum to be
consistently longer or shorter than the ﬁrst. It is the standard deviation of difference
(SDD) which is a reﬂection of reproducibility: narrow SDD indicates good reproduc-
ibility (repeated optimizations yield similar AV optima) while wide SDD indicates
poor reproducibility.
For completeness we also present R2 values between ﬁrst and second AV optima,
although it should be recognised that R2 is just as much a reﬂection of the width of
the spectrum of AV optima in the population studied, as of the reproducibility within
individuals.
2.4. Scatter and curvature, the determinants of the precision of the optimum
The more curved the hemodynamic response, the more precisely the optimum AV
delay can be identiﬁed [1]. Conversely the noisier (more scattered) the measurements
at each setting, the less precisely the optimum AV delay can be identiﬁed [1]. Scatter
(Fig. 2, panel a) is quantiﬁed as the standard deviation of repeated measurement for
the same AV delay (for convenience this can be averaged across different AV delays).
Curvature of the biological response is calculated as the quadratic coefﬁcient of the
parabola describing the curved response of hemodynamic data to changes in AV
delay (Fig. 2 middle panel b) [13].
The ratio between scatter and curvature is the biological determinant of the test–
retest variability of the optimum: higher ratios indicate greater variability [1]. We com-
pared the scatter:curvature ratio for each tested hemodynamic parameter in order to
compare precision when used for AVD optimisation (Fig. 2 panel c).
2.5. Statistics
The test–retest reproducibility of the apparently optimal AV delay was calculated
as the standard deviation of the difference between the two optima calculated from in-
dependent datasets. The correlation between the two optima was expressed as R2. We
used the F-test for equality of variances to test whether test–retest reproducibility was
signiﬁcantly different between methods of optimization. Paired comparisons were
made using Student's paired t test. A p value of b0.05 was taken as statistically signif-
icant. Microsoft Excel and Statview 5.0 (SAS Institute Inc., Cary, NC) were used to col-
late and analyse the data.
3. Results
3.1. Assessment of four different protocols for AV delay optimization
using left ventricular dp/dtmax
3.1.1. Test–retest reproducibility of the AV optimum
All 25 patients underwent the full reproducibility studies of the
immediate protocols. 15 of them also underwent reproducibility of
the delayed protocol.
The immediate absolute protocol had a standard deviation of differ-
ence between replicate optima (SDD) of 41 ms and R2=0.45. This
means that on 95% of occasions, a second optimization would give an
AV optimum within ±82 ms of the ﬁrst AV optimum. This 164 ms
wide spanmeans that knowing the result of one optimization gives vir-
tually no clinically useful information regarding the likely result of a
second optimization.
The delayed absolute protocol had a similarly wide SDD of 40 ms
and R2=0.5.Reproducibility was improved in the protocols that used alterna-
tions, where the immediate change in dp/dtmax was measured rela-
tive to its value at a reference AV delay. The single relative protocol
gave SDD=27 ms and R2=0.77. The multiple relative also had bet-
ter same day reproducibility, with SDD=23 ms and R2=0.79
(Fig. 3).
SDD was signiﬁcantly lower (i.e. reproducibility of the AV optimum
is signiﬁcantly better) for themultiple relativeprotocol thanwith the im-
mediate absolute protocol (pb0.01 by F-test) or the delayed absolute
protocol (pb0.01).
3.1.2. Biological variability (scatter) of dp/dtmax between successive
measurements
Variability in the apparent optimum arose from natural biological
variability in dp/dtmax values. Scatter between successive measure-
ments at the sameAV delay setting, calculated as the standard deviation
of difference, was: immediate absolute 57 mm Hg/s, delayed absolute
105 mm Hg/s, single relative 60 mm Hg/s and multiple relative
49 mm Hg/s. This means that, for example, if a patient has at a particu-
lar setting on a ﬁrst optimization a dp/dtmax measured by the standard
(delayed absolute) method of 900 mm Hg/s, on the next optimization
one can be 95% conﬁdent that the dp/dtmax will be in the range 900±
1.96×105 mm Hg/s, i.e. approximately 700 to 1100 mm Hg/s.
3.1.3. Comparison of the four tested dp/dtmax protocols with regard to the
AV delay identiﬁed as optimal
The single relative method showed moderate agreement with the
multiple relative algorithm R2=0.58, SDD=36 ms with regard to
the AV delay identiﬁed as optimal. However, the other two protocols
showed poor agreement with the multiple relative algorithm. For the
immediate absolute protocol SDD=66 ms and R2=0.18, while for the
delayed absolute protocol SDD=66 ms and R2=0.34 (Fig. 4). It should
be noted that it is not sustainably possible for two methods to agree
with each other any better than they agree with themselves [14].
3.2. Comparison of three different invasive measures for AV delay
optimization
3.2.1. Test–retest reproducibility
We compared test–retest reproducibility of three different invasive
hemodynamicmeasures. All three testedmeasureswere recorded simul-
taneously and we used an identical multiple relative protocol (mean
relative change obtained from a total of 6 transitions) to process the
hemodynamic data. Using this protocol all three measures showed simi-
lar reproducibility (Fig. 5). For LV dp/dtmax SDD 23 ms and R2=0.79, for
LV systolic blood pressure SDD=16 ms and R2=0.84, and for LV pulse
pressure SDD=21 ms and R2=0.76 (p=NS for all).
3.2.2. Drivers of precision of optimization: measurement scatter and curva-
ture of response
Overall, dp/dtmax had a standard deviation of 28.8 mm Hg/s, and cur-
vature of response 0.0034 mm Hg/s/ms2, giving a scatter:curvature ratio
of 8538 ms2. LV systolic blood pressure had a measurement of scatter of
2.54 mm Hg and curvature of response 0.00056 mm Hg/ms2, giving a
scatter:curvature ratio of 4532 ms2. For LV pulse pressure scatter was
2.59 mm Hg and curvature was 0.00034 mm Hg/ms2 giving a scatter:
curvature ratio of 7602 ms2. dp/dtmax has a different physical dimension
from the pressures, but both scatter and curvature reﬂect this, so that the
scatter:curvature ratio is in ms2, directly comparable between the three
measures.
3.3. Relative importance of AV delay optimization with regard to the
overall hemodynamic improvement observed with CRT
In addition to determining optimal AV delay, we also measured
the acute change in hemodynamics (dp/dtmax, LV SBP and LV PP)
Fig. 2.Method for calculating scatter and curvature which are the biological determinants of the reproducibility of the optimum AV delay. Data from one patient is shown in order to
describe how Scatter and Curvature can be calculated. Scatter is the spontaneous variability in measurements and is calculated as the standard deviation of the repeated measure-
ments (shown in panel a). Curvature expresses how quickly the underlying measurement declines with distance away from the optimum. It is approximately parabolic and it is
possible to calculate the underlying curvature by measuring the change in the acute hemodynamic parameter occurring over a known change in AV delay (panel b). The scat-
ter:curvature ratio is calculated for each tested hemodynamic parameter in order to compare precision when used for AVD optimisation. The ratio between scatter and curvature
is the biological determinant of the test–retest variability of the optimum: higher ratios indicate greater variability (panel c). SD: standard deviation.
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delay of 120 ms. We then calculated the percentage increase in the
three measured hemodynamic parameters, occurring as a result of
‘turning’ on CRT with a nominal AV delay. We compared this tothe hemodynamic improvement achieved with CRT with an ‘optimal’
AV delay.
To prevent bias [1], we measured the size of the advantage of the
optimal setting using completely separate data from that used to
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the relative contribution AV delay optimization had on the overall
maximal hemodynamic response to CRT.
Themean absolute values for the threemeasured hemodynamic pa-
rameters during AAI pacing at a heart rate of 90 bpm were LV systolic
blood pressure 126 mm Hg, LV dp/dtmax 1055 mm Hg/s and LV pulse
pressure 124 mm Hg.
3.3.1. Increment achieved by CRT at nominal AV delay
The mean percentage changes from baseline for these measures,
with the onset of CRT with the nominal AV delay (AVD 120 ms)
were: LV systolic pressure 2%, LV dp/dtmax 5% and LV pulse pressure
3%.
3.3.2. Unbiased estimate of increment achieved by CRT at optimal AV
delay
Simply selecting the highest value of a set of noisy numbers and com-
paring it to a reference value, will produce an artefactual positive bias
(since the value selected tends to be the one with the most positive
noise). To avoid this bias, we deﬁned the AV optimumwith one dataset,
and made measurements of effect size with a separate dataset. The per-
centage increase from a baseline of AAI pacing to the separately-
determined optimal AV delay was 6%, 9% and 6% for LV systolic BP, LV
dp/dtmax and LV pulse pressure respectively.
3.3.3. Increment contributed by AV optimization expressed as a percentage
of the increment contributed by CRT at nominal AV delay
The extra increment AV delay optimization contributed over and
above the increment given by nominal-AVD CRT can be expressed as
a percentage of the increment given by nominal-AV CRT. On this
scale, a value of 0% would indicate that AV optimization contributesnothing extra beyond nominal AV, and 100% would indicate that AV
optimization doubles the impact of CRT at nominal AV.
For dp/dtmax AAI to CRT 120 ms raised the value by 60 mm Hg/s,
and then CRT 120 ms to optimal AV raised the value by a
further 42 mm Hg/s, therefore the additional improvement from AV
optimization, expressed as a multiple of the CRT 120 ms effect, was
42/60 i.e. an additional 70%. For LV SBP, AAI to 120 ms raised pressure
by 2.7 mm Hg, and then 120 ms to optimal raised it a further
4.3 mm Hg, therefore the additional increment from AV optimization
expressed as a multiple of the CRT 120 ms effect, was 4.3/2.7=160%.
For LV PP, AAI to 120 ms added 3.3 mm Hg, and 120 to optimal AV
added a further 4.1 mm Hg, therefore the additional increment from
AV optimization expressed as a multiple of the CRT 120 ms effect, was
4.1/3.3=124%.
3.4. Magnitude of reduction in dp/dtmax as a result of programming a
non-optimal AV delay
We assessed the hemodynamic consequence of progressively chang-
ing the AVdelay away fromoptimal. Ifwe used the samedataset to select
the optimum, as the dataset used to measure the increment obtained
from optimization, that increment would be artefactually biased up-
wards (since it would disproportionately often contain a positive noise
value). To eliminate this bias we used one dataset to identify optimal
AV delay, and a numerically-separate dataset to measure the hemody-
namic consequences of programming non-optimal versus optimal AV
delay.
We found that the magnitude of reduction in dp/dt progressively
increased the further from optimal that the AV delay was programmed.
Even relatively small changes away from optimal resulted in signiﬁcant
reductions in acute dp/dtmax (Fig. 6). For example programming an AV
delay 40 ms longer or shorter than optimal resulted in a signiﬁcant fall
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gramming an AV delay 40 ms longer than optimal was −27 mm Hg/s
that is 45% of the hemodynamic beneﬁt obtained from turning CRT on
compared to baseline of AAI pacing (AAI to nominal AV delay of
120 ms=mean increase of 60 mm Hg/s).
4. Discussion
This study is a critical analysis of the fundamental properties of
dp/dtmax when used for AV delay optimization. The measurement ofLV  Systolic b
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duce a more reproducible optimum. Second, signal-to-noise ratio, name-
ly the relative sensitivity of a physiological variable to changes inAVdelay
versus random scatter, is higher for systolic pressure than for dp/dtmax.
Third, AV delay optimization using the more reproducible method
approximately doubles the acute hemodynamic (dp/dtmax) increase
available from CRT at a nominal 120 ms setting. The, effect sizes of opti-
mization were measured from an independent dataset to prevent the
positive bias which occurs when increment from optimization is mea-
sured from the same dataset as the optimum is selected.
4.1. Processing the dp/dtmax signal to improve precision of optimization
We found that simply using an absolute measurement of dp/dtmax,
without comparison to a reference AV delay, yields AV optima with
poor test–retest reproducibility. This is the case regardless of whether
dp/dtmax is recorded immediately after a transition to the tested AV
delay or if the onset of the recording is delayed by 30 s to allow for
‘stabilisation’ of the dp/dtmax trace. This is an important ﬁnding as
both of these methods are used in clinical practice for AV delay opti-
mization. If the reproducibility is poor it is extremely unlikely that the
optimization process will result in identiﬁcation of the true ‘optimal’
value and indeed may identify a value which is worse than not
performing an optimization at all.
There was a trend to improvement in reproducibility of the opti-
mum when multiple replicates were averaged for each optimization,
but even with 6 replicates, taking 1 min per optimization, the SD of dif-
ferencewas 23 ms. This means that if an optimumwas on one occasion
found to be 140 ms, then on a second occasion, 95% of the time it would
lie between 140 ms−46 ms and 140 ms+46 ms. This constitutes a
range of uncertainty 92 ms wide. If a clinician requires better precision
than this, and wishes to use dp/dtmax, then more than 6 replicates
would be required.
Clinicians and researchers designing protocols for optimization
should start with their desired level of precision of the optimum
and then use standard methods to ensure that their protocols deliverit [1]. Many widely used optimization protocols, even if conducted
carefully, cannot deliver reproducible optima [1].
4.2. Drivers of precision of optimization, and choice between pressure
and dp/dtmax
The driver of reproducibility of the optimum is the signal-to-noise
ratio, namely the size of the changes caused by alterations in AV delay
in relation to the size of the changes occurring spontaneously.
In this study we quantiﬁed signal as the curvature parameter of the
quadratic ﬁt of the hemodynamic response to adjusting AV delay, and
noise by the standard deviation of the measurements at an unchanged
AV delay. The advantage of this approach is it allows technologies to be
compared between protocols that cover different ranges of AV delays.
Systolic pressure appears to show advantages over LV dp/dtmax,
which suggests that in larger studies, optimization by systolic pressure
might be expected to provide a more reproducible optimum than opti-
mization bydp/dtmax. The lower signal-to-noise ratio for dp/dtmax occurs
because even though the signal in dp/dtmax is a larger percentage of
mean value than the signal in BP, the noise is a much larger percentage
of mean value than the corresponding noise in BP.
4.3. Source of “noise”
In this study we use the term noise to encompass all sources of vari-
ability betweenonemeasurement andanother, of a physiological variable
such as LV dp/dtmax or pressure. From a statistical and practical point of
view, all sources of such variability conspire to impair precision of identi-
ﬁcation of the AV optimum. Separating the sources might be useful if it
leads to identifying strategies for reducing speciﬁc sources of noise. Our
study does not attempt to separate the sources, but rather to quantify
the composite size of noise and examine its implications for studies of
AV optimization (and related ﬁelds such as lead position optimization).
We have previously observed that biological beat-to-beat, breath-
to-breath variability is substantial, and occurs concordantly in simulta-
neous measurements made over 50 cm apart in the circulation, using
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mal aorta versus servo-pressure system in ﬁnger cuff at ﬁnger) and
recorded on independent equipment (Figure 1 of Reference 18 [15]).
4.4. Incremental contribution of optimization: method for measuring
without bias
A weakness of any study that makes measurements at several set-
tings, adopts the setting giving the highest measurement as the opti-
mum, and then re-uses the same measures to determine the “beneﬁt”
of this setting, is that such a protocol artefactually inﬂates the “beneﬁt”
of the optimum setting [1]. This is particularly important if the noise is
large or the differences observed in the measured parameter between
the tested settings are small. This is because – in those circumstances –
the measurement at the apparently optimal setting is likely to include
a markedly positive error component (which is responsible for making
it the apparent optimum) and therefore averaging the increments at
these apparent optima across all patients tends to accumulate a series
of positive errors rather than cancelling out positive with negative
errors.
To prevent this bias (Illusion 2 and Figure 1 in Reference [1]) it is
important to measure the size of the advantage of the optimum using
completely separate data from the data used to decide which setting
is the optimum. By this bias-resistant approach, we found that be-
yond the initial increment from switching on CRT at a nominal setting
of 120 ms, the additional increment from AV optimization was 69%
(dp/dtmax) to 160% (LV SBP).
4.5. How can optimization be important and unimportant?
If theseﬁgures are representative of the general population of patients
receiving CRT then reproducible AV optimization would be expected to
have a discernible clinical endpoint effect.
Some AV optimization protocols, tested in adequately-powered,
bias-resistant fashion via large, randomized, controlled, externally-
monitored trials, delivered no statistically signiﬁcant effect on end-
points. What has not been reported is whether these tested algo-
rithms are reproducible.
For example the SMART-AV study was not conducting reproducible,
quantitative optimization of physiological response, but instead used
two different methods [7]. One was a selection of AV delay based on
qualitative judgement of transmitral Doppler pattern, whose blinded
test–retest reproducibility was not reported and may be poor [16].
The other did not utilise physiological responses.
4.6. Magnitude of reduction in dp/dt max as a result of programming a
non-optimal AV delay
This study indicates that even small changes in the programmed AV
delay away from optimal signiﬁcantly reduce acute hemodynamics.
Nearly 50% of the beneﬁcial effect obtained by turning CRT on, is lost
if the AV delay is programmed 40 ms longer or shorter than optimal.
This suggests that optimization algorithms need to have a narrower
within-patient conﬁdence interval than ±40 ms.
4.7. Reproducibility of invasive dp/dt optimization in the context of poor
reproducibility of non-invasive optimization strategies
This study addresses only invasive optimization, which is an approach
often used in research studies. In routine clinical practice, if optimization
is carried out, the approach is usually non-invasive.
Themost commonly used non-invasivemethod for AV optimization
is echocardiographic transmitral Doppler. However, the blinded test–
retest reproducibility of the optimum on two separate optimisations,
is not known. We have previously abandoned plans to conduct blinded
test–retest reproducibility of transmitral Doppler optimization when wefound that even in the idealised situation of a just a single optimization
dataset printed onto large sheets of paper, there is poor agreement be-
tween experts, and indeed poor agreement within the same experts
re-asked a few minutes later [16,17]. There is therefore no possibility
that blinded test–retest reproducibility of transmitral Doppler optimiza-
tion by the methods classically described is good enough for it to be
used as a reference standard for testing another optimization method.
Narrow within-patient conﬁdence intervals of the optimum are
more easily obtained using automatically quantiﬁable variables such
as pressure, because several replicate measurements can easily be
made at each setting [18]. The test–retest reproducibility of the best
invasive optimization methods described in this study (SDD of repli-
cate optima for LV SBP=16 ms) is similar to that reported using
some non-invasive methods (SDD of replicate optima=14 ms [15]).
4.8. Clinical implications
Even performing invasive, intraventricular measurements does not
grant immunity to biological noise, which is important to recognise in
the design of optimization protocols. Obtaining data invasively from
the ventricle eliminates some sources of measurement error, such as
probemovement disturbing consistency of aortic outﬂow tract velocity
time integral (VTI) during Doppler optimization. However the invasive
approach does not eliminate genuine biological variability, and this is
not trivial in magnitude compared to the size of genuine differences
being studied between settings.
Determining an optimum AV delay by reproducible methods, and
then (from separate data) calculating the increment in hemodynamics
beyond CRT at AV 120 ms, suggests that optimization of AV delay de-
livers hemodynamic beneﬁts about as large as that of AV 120 ms CRT it-
self. This may at ﬁrst seem to contradict clinical data which have
demonstrated clear symptom, remodelling and mortality beneﬁts of
CRT but not of optimization. However the methods used in those opti-
mization studies have not yet been demonstrated to have narrow
test–retest reproducibility and therefore should not be assumed to be
delivering incontrovertible, reliable optima.
4.9. Study limitations
This study was designed to compare test–retest reproducibility of
the optimization protocols assessed, and not designed to assess out-
come measures such as symptoms or mortality of utilising these opti-
mization protocols. It has adequate size and precision to answer the
questions being addressed.
Ensuring that optimization protocols deliver reproducible optima
is a crucial ﬁrst step that must precede the design of clinical trials of
the efﬁcacy of optimization, because they will need to be very large
in order to adequately test for clinical beneﬁts. For example, even if
the clinical beneﬁts of reproducible optimization are approximately
half those of standard CRT, then it might still be worthwhile (since
inconvenience to the patient would be small compared to CRT im-
plantation itself) but the trials required to demonstrate this would
need to be 4 times the size of those designed to show clinical beneﬁts
of CRT implantation.
In this study we kept heart rate ﬁxed at an elevated rate of 90 bpm.
We did not attempt to assess the effect of heart rate on reproducibility,
because it is already known that at lower heart rates, the hemodynamic
response to adjusting AV delay is less curved and therefore it is harder
to discern the optimum [11]. Because the test–retest reproducibility of
the optimum is critically dependent on this curvature [18], at lower
heart rates the test–retest reproducibility of the optimum should be
wider. It should be noted that pacing at an elevated ﬁxed heart rate,
supine and at rest may not reﬂect clinical practice and therefore the
AV delay determined as optimal in these circumstances may not be
the same as in an ambulatory upright patient with a variably changing
heart rate.
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by researchers risks distorting ﬁndings [19], and even if carried out
without bias might be difﬁcult to replicate in exactly the same way in
future experiments. Our algorithm addresses the beats immediately be-
fore and immediately after the change in setting, i.e. with no beats omit-
ted. The reason for this is that these beats have the smallest opportunity
for “drift noise” to develop between them, and because the “signal” is
greatest in that early post-transition window of time. These consider-
ations turn out to be quantitatively more important than the greater
“between-beat noise” in that time window [20,21].
5. Conclusions
For AV delay optimization of CRT, invasivemeasurement of dp/dtmax
provides conﬁdence that physiological responses are being measured
directly but this gold standard, alone, is not sufﬁcient to guarantee pre-
cise optimisation, i.e. reproducible optimadetermined between test and
retest with independent data. Spontaneous biological variability over
time (noise) is not necessarily trivial in comparison to the genuine dif-
ferences between settings (signal).
Improved reproducibility of the optimum is achieved when dp/dtmax
measurements are calculated relative to immediately preceding mea-
surements at a standard reference AV delay, and – most importantly –
multiple measurements are made. Even with the 6 replicate measure-
ments we made at each AV delay, the level of uncertainty is wide:
SDD=23 ms; 95% conﬁdence interval of difference between two optimi-
zations in same patient=±46 ms. Any level of precision may be
obtained if enough replicates are measured [18], because these values
will fall with the square root of the number of replicates. Clinicians and
researchers designing protocols for optimization could start from a de-
sired level of precision of the optimum, and then design their optimisa-
tion protocol to deliver it [18].
Signal-to-noise ratio is higher for systolic pressure than for dp/dtmax,
which may confer advantages for ensuring reproducible AV optimiza-
tion. Reproducible AV optimization provides elevation in the hemody-
namic increment achievable from CRT beyond what is achieved from
a CRT with nominal AVD of 120 ms: by approximately twofold.
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